Form 4: Pfizer Director Ronald E. Blaylock Reports Acquisition of Phantom Stock Units

Director Ronald E. Blaylock reports acquisition of 8,999 phantom stock units of Pfizer Inc. on April 24, 2025, as part of deferred compensation.

Summary

• Ronald E. Blaylock, a director of Pfizer Inc., filed a Form 4 on April 28, 2025, reporting a transaction.
• On April 24, 2025, Blaylock acquired 8,999 phantom stock units.
• These units were granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of common stock.
• The price of the phantom stock units is $22.78.
• Following the reported transaction, Blaylock beneficially owns 71,373.806 phantom stock units.
• These units represent deferred director's compensation that are settled in cash or common stock at the director's election following retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally. The acquisition of phantom stock units can be seen as a positive sign of alignment with company performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The deferred compensation plan may incentivize continued service on the Board of Directors.

Industry Context

This filing is a routine disclosure related to director compensation and is common among publicly traded companies. It reflects standard practices for aligning director interests with shareholder value.

Comparison to Industry Standards

• Deferred compensation plans, including phantom stock units, are a common practice among large pharmaceutical companies like Johnson & Johnson, Merck, and AbbVie to attract and retain board members.
• The specific terms of Pfizer's plan, such as the vesting schedule and settlement options, would need to be compared to those of its peers to assess its relative competitiveness.
• The amount of phantom stock units granted to Mr. Blaylock can be benchmarked against similar grants to directors at comparable companies to determine if it is within the typical range.

Stakeholder Impact

• Shareholders may view the director's acquisition of phantom stock units positively, as it aligns their interests with the company's long-term success.

Key Dates

Keywords

Form 4, Pfizer, Director, Blaylock, Phantom Stock Units, Deferred Compensation, Beneficial Ownership